Company: MDCXW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001062993-25-010738
Chunk: 2

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-03
Form: 424B3
Chunk 2
---
 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter). Emerging growth company ☑ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On May 29, 2025, Medicus Pharma Ltd. ("Medicus" or the "Company") entered into a Placement Agency Agreement (the "Placement Agency Agreement") with Maxim Group LLC, as representative of the placement agents named therein (the "Placement Agents"), relating to a public offering of 2,260,000 units, each unit consisting of one common share, no par value, of the Company, and one warrant to purchase one common share, at a price of $3.10 per unit (the "Offering"). Each warrant is immediately exercisable for one of our common shares at an exercise price of $3.10 per share and will expire five years from the date of issuance. In connection with the Offering, the Company entered into a subscription agreement (the "Subscription Agreements") with a certain investor (the "Investor").

The aggregate gross proceeds to the Company from the Offering, which closed on June 2, 2025, were $7,006,000, before deducting placement agent fees and other estimated offering expenses. The Company expects to use the net proceeds from the Offering to fund its Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch. The Company may also use the net proceeds of the Offering to expand its exploratory phase 2 clinical trial to a pivotal trial and/or to expand its trials to cover other non-melanoma skin diseases. The Company expects to use any remaining net proceeds for general corporate purposes and working capital.

The units were offered pursuant to the Company's Registration Statement on Form S-1 (the "Registration Statement"), initially filed with the Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended (the "Securities Act") on May 27, 2025 and declared effective by the SEC on May 29, 2025.

Pursuant to the terms of the Placement Agency